Results from the SOUL Trial: The Cardiologists' Perspective

Show notes

Watch the full video on YouTube to explore the cardiologist’s perspective on one of the most important cardiovascular outcomes trials in recent years.

In this episode, Vivienne Parry speaks with Dr Matthew Cavender (University of North Carolina) about the SOUL trial, which evaluated the cardiovascular impact of oral semaglutide in more than 8,000 people with type 2 diabetes.

They discuss:

  • How oral semaglutide reduced major cardiovascular events by 14%
  • Why an oral GLP-1 receptor agonist may broaden access and adherence
  • Implications for diabetologist's, cardiologists and primary care
  • How team-based care can improve uptake of evidence-based therapies
  • What the latest ESC guidelines mean for future prescribing

🎧 Listen now for a clear, accessible breakdown of a landmark study reshaping diabetes and cardiovascular risk management. To learn more about our expert speaker:

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.